All products / DC9517
Cisatracurium (besylate)
Pack sizes and prices
| Pack size | Price |
|---|---|
| 1 g | $1,100 USDRequest a quote → |
In stock. Contact our team for lead time, shipping and final quotation.
Product overview
Cisatracurium Besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission. Cisatracurium is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC9517 |
|---|---|
| Product name | Cisatracurium (besylate) |
| CAS | 96946-42-8 |
| Molecular formula | C53H72N2O12.2(C6H5O3S) |
| Molecular weight | 1243.48 |
| Purity | >98% |
| SMILES | C[N@@+]1(CCC(OCCCCCOC(CC[N@@+]2([C@H](CC3=CC=C(OC)C(OC)=C3)C3C(=CC(=C(OC)C=3)OC)CC2)C)=O)=O)[C@H](CC2=CC=C(OC)C(OC)=C2)C2C(=CC(=C(OC)C=2)OC)CC1.[O-]S(C1=CC=CC=C1)(=O)=O.[O-]S(C1=CC=CC=C1)(=O)=O |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — Cisatracurium (besylate) (DC9517)Source references
[1]. Dear, G.J., et al., Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom, 1995. 9(14): p. 1457-64. [2]. Serra, C.S. and A.C. Oliveira, Cisatracurium: myographical and electrophysiological studies in the isolated rat muscle. Fundam Clin Pharmacol, 2006. 20(3): p. 291-8.
